• 5hmC is globally depleted in MM and even more in advanced stages of the disease.
Introduction
Multiple Myeloma (MM) is a plasma cell (PC) neoplasm with an incidence rate of 5/100,000 in Europe and accounts for approximatively 1 percent of all cancers. Median survival of patients has greatly improved in the last decade 1 with the use of novel strategies such as autologous stem cell transplantation and new sets of drugs: immunomodulators, proteasome inhibitors, histone deacetylase (HDAC) inhibitors and monoclonal antibodies. 2 Yet treatment remains challenging as nearly all patients ultimately relapse with the emergence of a resistant subpopulation of malignant plasma cells. Malignant clones show an heterogeneous range of mutations and chromosomal abnormalities along with heterogeneous chromatin and epigenetic dysregulations at diagnosis and at relapse that affects biological pathways (MAPK, NF-κB, DNA-repair). 3 Genomic and transcriptomic studies have allowed a better understanding of the disease and identified key transcription factors involved such as IRF4, MYC, PRDM1 and XBP1. [3] [4] [5] Recent epigenomics technologies can help to deepen our knowledge of the transcriptional programs shaping MM. However epigenomics analysis through histone marks profiling with chromatin immunoprecipitation (ChIP-seq) or open chromatin mapping with Assay for Transposase-Accessible Chromatin (ATAC-seq) can be hard to set up on a cohort with limited material over a long range of time and thus give limited insights on the disease establishment and relapse. Studying DNA epigenetics marks is more adapted to this challenge. Agirre and colleagues 6 described DNA methylation in an important number of MM samples. They identified very heterogeneous levels of methylation from one patient to another. They found that despite a global hypomethylation, local and extensive hypermethylation is present in MM at intronic enhancer regions that are associated with stem cell development.
Chatonnet and colleagues 7 recently identified several hydroxymethylated CpGs in MM samples with limited association to disease severity or prognosis, and to our knowledge, the genome-wide mapping of 5hmC (hydroxymethylome) has never been studied in a well-established cohort.
Oxydative states of 5-methylated Cytosine (5mC) on genomic DNA have been identified a decade ago 8-10 : 5hmC, 5fC and 5caC. The TET proteins TET1/2/3 are responsible for the 5mC oxidation. 5fC and 5caC are almost undetectable in genomic DNA unless the glycosylase TDG gene is knocked-out 11, 12 , whereas 5hmC can be found in all cell types at various levels [13] [14] [15] . 5hmC is believed to be a DNA demethylation intermediate in a process involving TET proteins, TDG and the Base Excision Repair system. 16 However 5hmC is also shown as a stable DNA modification. 17, 18 Despite this discrepancy, 5hmC is commonly accepted as a DNA mark associated with active chromatin [19] [20] [21] and is a powerful way to identify active genomic regions associated with a disease directly from genomic DNA or more recently from circulating DNA. 22, 23 In this study, we characterized the 5hmC signal genome-wide on plasma cell DNA from 40 patients newly diagnosed with MM between 2010-2012 and representative of the main molecular subtypes, including 4 paired relapse samples, and of the plasma cells of 5 control individuals.
Patients selection for this study
In this study, we have selected 40 patient samples with: low level or absence of RNA in DNA samples, low level of rRNA in RNA-seq data, enough DNA material available (at least 1 ug) and high percentage of CD138+ cells (98% in average in this study).
Digest of genomic DNA and subsequent LC-MS analysis
The genomic levels of methylcytosine (mC) and hydroxymethyl-cytosine (hmC) were quantified using a mass spectrometry-based stable isotope-dilution method. 26 For each LC-MS-measurement (technical replicate), 70 ng of genomic DNA (gDNA) were digested to the nucleoside level using the Nucleoside Digestion Mix (ref. M0649S) from New England BioLabs. To this reason, a solution of 70 ng gDNA in 38 µL of milliQ-water was prepared. As heavy-atom-labeled internal standards, 1.28 pmol D 3 -mC and 0.193 pmol D 2 15 N 2 -hmC in 6 µL of milliQ-water were added to the solution, followed by 5 µL of the Nucleoside Digestion Mix Reaction Buffer (10x), and 1 µL of the Nucleoside Digestion Mix. After incubation for 90 min at 37°C, the mixture was filtered using an AcroPrep Advance 96 filter plate 0.2 µm Supor from Pall Life Sciences and subsequently analyzed by LC-MS. For each biological sample, two independent measurements (technical replicates) were performed. Quantitative LC-ESI-MS/MS analysis of the enzymatically digested DNA samples was performed using an Agilent 1290 UHPLC system coupled to an Agilent 6490 triple quadrupole mass spectrometer. The UHPLC-conditions used and the settings of the mass spectrometer were the same as previously published by Traube and colleagues. 26
Selective chemical labeling of 5hmC coupled with sequencing (5hmC-seq)
For each sample, 550 ng of genomic DNA was sonicated with a Bioruptor Pico in Tris 10 mM pH 8 to obtain DNA fragments of 300 bp in average. 25 pg of 5hmC control spike-in were added to the sonicated DNA (control provided by the kit HydroxyMethylCollector, Active Motif, ref. 55013). 50 ng of DNA was conserved at this stage to make the input library later. The remaining DNA was processed using the HydroxyMethylCollector kit (method from Song and colleagues 27 ) to glycosylate and biotinylate specifically the genomic 5hmC. After glycosylation and biotinylation the DNA was purified with Ampure beads (Beckman Coulter, ref. A63881) . The DNA fragments containing the biot-glu-5hmC were purified with Streptavidine beads (Active Motif, ref. 55013), eluted, purified with Ampure beads and finally eluted in 50 uL Tris pH 8. The 5hmC-seq libraries were prepared with the kit NEBNext Ultra II DNA library prep kit for Illumina (ref. E7645S) and indexed with NEBNext dual indexed primers (E7600S). The libraries were quality-checked by HS DNA Agilent BioAnalyzer ( Supplementary Figure 1) , dosed by DNA HS Qubit, pooled and submitted to the genome sequencing platform for Single-Read 50 bp Illumina HiSeq-2500 Rapid Run sequencing.
RNA-seq librairies
As the IFM-DFCI did not include RNA-seq data from patients at relapse, we produced RNA-seq data at diagnosis and at relapse on 4 selected MM patients (patients number MM 2, MM 5, MM 7 and MM 21 
Bioinformatics 5hmC-seq analysis
5hmC-seq libraries were trimmed with Cutadapt v1.18 28 and mapped to human reference genome GRCh38 using Bowtie2 v2.2.8 29 with default parameters. Duplicates and reads of low mapping quality (Q < 30) were discarded. 5hmC peak clusters were defined similar to Boeva and colleagues 30, 31 with a stitching distance of 12.5kb (Supplementary Figure 2 ). Blacklisted regions consist of chromosomes X, Y, ENCODE reference blacklist and peaks called on input-seq libraries.
Genes and 5hmC peaks clusters were associated to the Topologically Associated Domain (TAD) of the B-cell derived cell line GM12878 they are located in similar to Boeva and colleagues. 31 Group specific 5hmC peaks clusters were identified by computing the average Log2 Fold-Change signal per region between groups and tested with a Wilcoxon rank-sum test adjusted with a Benjamini-Hochberg correction. For paired samples (two replicates of each diagnosis and relapse), we used DiffBind 32 with default parameters to find differentially enriched 5hmC regions.
Potential transcription factor binding sites and core regulatory circuiteries were found with CRCMapper and MEME. 33, 34 Network clustering of 5hmC was computed on the correlation matrix of peak clusters in the cohort. A graph adjacency matrix was calculated from the correlation between peak clusters with a threshold of 0.715. Every correlation above 0.715 is counted as an adjacency between two peak clusters. This value was chosen to limit the number of non-connected components in the graph and to keep about 400 peak clusters in the analysis. The two sub-networks were then identified from the hierarchical clustering (Ward's method) of the first two Eigen components of the symmetric normalized Laplacian matrix. 35 Bioinformatics code is hosted at: https://gitlab.univ-nantes.fr/alberge/5hmc-myeloma-analysis.
RNA-seq analysis
IFM-DFCI RNA-seq data were obtained from Cleynen and colleagues 36 or sequenced by us. RNA-seq libraries were trimmed using Cutadapt v1.13 28 with parameter −m 20 and aligned to hg38/GRCh38 using STAR v2.5.3a 37 with default parameters. Genes were quantified using featureCounts 38 from the R package Rsubread and the Gencode v28 genome annotation. RefSeq genome annotation was used in parallel as a reference for transcription factor selection.
ChIP-seq and ATAC-seq analysis
ChIP-seq and ATAC-seq libraries were downloaded from the European Nucleotide Archive (project number PR-JEB25605 39 ) and treated with the pyflow-ChIPseq 40 and pyflow-ATACseq pipelines respectively with default parameters. Chromatine-states genome annotation was realized using ChromHMM 41 on ChIP-seq data from MM.1S cell line.
Survival analysis
Time-to-event was calculated from the randomization to the event date, i.e. death for OS, death or relapse for PFS, or to the last follow-up date.
For MS quantitative variables, cohorts were split at the median value of high and low 5hmc (and 5mC). Survival curves were calculated using the Kaplan-Meier method and groups were compared using a Log-rank test.
For 5hmC-seq data, at univariate step, SAM 42 was run to extract the 5hmC regions that are significantly correlated with overall survival (q value < 0.05) with 100 permutations and ∆ = 0.2. For multiple regions testing (scores SC1 and SC2), the cohort was split at median value of 5hmC enrichment. 5hmC of each patient was summarized by the weighted mean of independently significant parameters. Variables were standardized and weights were based on multivariate Cox's coefficients changed to +1 or −1 according to their sign to avoid overfitting. Survival curves were calculated using the Kaplan-Meier method and groups were compared using a Log-rank test.
Data Sharing Statement
Sequencing data are accessible at ENA under accession PRJEB32800. Mass spectrometry data are available in Supplemental Table. Results
The 5hmC regions landscape in MM
We studied a cohort of 40 patients newly diagnosed with MM between 2010-2012 and 5 healthy bone marrow donors ( Figure 1A) .
We quantified by MS the global level of 5mC and 5hmC in our 49 samples (40 diagnosis in 5mC, 39 in 5hmC, 4 relapses and 5 normal plasma cell samples). We found the 5mC and the 5hmC to be both significantly reduced in MM compared to normal plasma cells (NPC; Figure 1B and Supplementary Figure 3A ). The amount of 5hmC is reduced in average by about 4 fold between NPC and MM (p value <0.001). We found that 5hmC, and not 5mC, is reduced in MM Stage II/III compared to Stage I regarding to the International Staging System, 43 a classification of patients based on β 2 -microglobulin and albumin levels with a strong prognosis value (p value =0.025, Figure 1C and Supplementary Figure 3B ). 5mC and 5hmC global levels were not correlated to the sex or the age of the patients (Supplementary Figure 3C -3F).
These results encouraged us to characterize the hydroxymethylome by 5hmC-seq 27 to identify the residual genomic regions marked by 5hmC in MM.
We confirm that the level of 5hmC signal in enriched at gene bodies and is positively associated with RNA expression as expected from previous studies 20, 27, [44] [45] [46] ( Figure 1D ).
The 5hmC signal is particularly enriched at strong enhancers and to a lesser extend at weak enhancers ( Figure  1E ) when we used a functional annotation from the MM.1S cell line.
Inspection of regions of interest showed that strong levels of 5hmC can be associated between distal loci ( Figure  1F ). For instance at the CCND2 locus, we found a strong correlation (R 2 = 0.88) between 5hmC signal in the gene body (chr12:4,278,700-4,312,900) and 5hmC signal at an extragenic centromeric region located 120 kb upstream (chr12:4,106,500-4,164,700; Supplementary Figure 4A ). Both 5hmC signals correlate well with CCND2 RNA expression and both regions are located in the same topogical domain according to HiC data 47, 48 (chr12:3,850,000-4,800,000; Supplementary Figure 4B ). The upstream region is also marked by ATAC and H3K27ac signals in MM patients 39 suggesting that this genomic region is functionally active. This strongly suggests that this upstream region is an enhancer of CCND2 gene.
Hence we pursued the analyses using 1816 5hmC peak clusters. We determined the 5hmC peak clusters common to at least two patients and performed an unsupervised Principal Component Analysis (PCA). PCA plot shows a great heterogeneity of MM compared with Normal patients (Figure 2A ). PC1 is driven by CCND1 (x-axis, left-side) versus CCND2 (x-axis, right-side). PC2 is driven by CCND1 (y-axis, bottom) versus FGFR3 -MMSET (y-axis, top) (Supplementary Table) , the three loci being of major interest in MM. Patients samples were then classified in 5 groups: MMSET (translocation t(4;14); 9 patients), CCND1 (RNA expression over 800 Transcripts per Million; 11 patients), hyperdiploid (16 patients, at least 2 odd chromosomal gains), others (MM in none of the aforementioned groups; 4 patients) and normal plasma cells (Normal; 5 donors).
For each group, we determined specific 5hmC peak clusters ( Figures 2B, 2C , Supplementary Figure 5A and Supplementary Table) . Remarkably, the strongest specific 5hmC peak cluster for the group MMSET is the locus FGFR3 -MMSET (p value =1.6 10 -6 ) followed by CCND2, LILRB4, NBEA and TRMT9B ( Figure 2D and Supplementary Figure 5B ). This strong 5hmC enrichment in MMSET patients is also associated with strong H3K27ac and ATAC-seq signals 39 compared to the other MM patients. This result suggests that the translocation between the FGFR3 -MMSET locus and the IgH locus is associated massive 5mC oxidation together with chromatin opening and very high transcription level ( Figure 2D ).
Remarkably, in patients from the CCND1 group, the strongest and most specific 5hmC peak cluster was located in the CCND1 gene itself ( Figure 2C and Supplementary Figures 5C, p value =0.05). Again this suggests that the translocation event between CCND1 and IgH or the novel overexpression of CCND1 induces very high 5mC oxidation together with a strong CCND1 transcription activity even though the classification of CCND1 patients was done based on RNA level in absence of FISH data.
The hyperdiploid group shows strongly specific 5hmC signal at HGF (Hepatocyte growth factor, p value =0.02) and at the locus of MYC oncogene ( Figure 2B , 2C, Supplementary Figure 5D , p value =0.02).
Normal plasma cells are enriched in 5hmC at BTNL8, C11orf80, ITM2C, PSG4 and TRIO genes ( Figure 2B , 2C). We found high 5hmC signal together with H3K27ac and ATAC signals 39 at several important genes implicated in MM including CCND1, FGFR3 -MMSET, IRF4, PRDM1 and XBP1 ( Supplementary Figures 6A-F) . Specifically, H3K27ac super-enhancers from a patient with t(4;14), del13 and amp1q from Jin and colleagues 39 and the 5hmC peak clusters found in one of our patients with the same genomic alterations are located at similar genomic loci CREB3L2, FNDC3B, MMSET, ST6GAL1 and ZBTB38 ( Supplementary Figures 5E,F ).
Transcriptional regulatory networks in MM
To uncover transcriptional regulation networks shaping multiple myeloma, we next measured the signal correlation between the 1816 5hmC peak clusters among the 40 patients and searched for correlation networks. A correlation matrix of 407 5hmC peak clusters was obtained, in which 2 correlation networks (network 1 and network 2, Figure  3A ) were defined through hierarchical clustering (of resp. 242 and 165 5hmC peak clusters). To find the core transcription factors (TF) involved in these 2 networks, we did a core transcriptional regulatory circuits analysis 34 for each patient based on 5hmC and RNA expression data. We found that core TFs motifs were differently enriched between the 2 networks. Network 1 was enriched with TFs motifs such as KLF6/13, MYC, SP3, SREBF2, TCF3, USF2 and ZBTB7A, while network 2 was enriched with ARID3A, ATF4, FOXO3, IRF4/7, NFIL3 and PRDM1 motifs ( Figures 3B, 3C, 3E ). The ten most expressed TF were ATF4, KLF6/13, IRF1/4, PRDM1, TCF3, USF1/2 and XBP1 (Supplementary Figure 7A ). These core transcription factors are shared between the two networks (Supplementary Figure 7B ). For each patient, we averaged 5hmC signal in networks 1 and 2 and found the patients to be continuously distributed in terms of network scores rather than being clustered in one of the networks ( Figure 3D ). Through GREAT analysis, 49 network 1 was shown to be associated with negative regulation of cytokine production and negative regulation of tumor necrosis factor production, while the network 2 was associated with immune response-regulating cell surface receptor signaling pathway and immune response-regulating signaling pathway ( Figure 3F ). Network analysis suggests that MM could be shaped by 2 regulation networks associated with specific transcription factors with partially redundant functions.
5hmC dynamics between diagnosis and relapse in MM
To identify the genomic regions associated with MM progression, we next mapped 5hmC in 4 MM pairs (diagnosis and first relapse) and identified differentially hydroxymethylated regions with two replicates for each condition ( Figure  4A ). CNV microarray data 50, 51 and RNA-seq were used at both time points to assess the progression of each patient ( Figure 4B ).
The plasma cells of patient MM 2 showed a translocation of the MMSET locus (t(4;14)) with a deletion of chromosomes 1p, 13 and 17p at diagnosis. This subject progressed in 18 months, with his plasma cells displaying a third copy of 1q. Out of 560 consensus 5hmC regions, 269 (48%) are significantly reduced at relapse compared to diagnosis (FDR<0.05) while 20 (3.5%) are enriched at relapse, suggesting a global loss of 5hmC. Interestingly, we noted a significant gain of 5hmC at CCND2 and IKZF1 genes bodies at relapse (respectively 1,6 and 1,5 fold) associated with a higher transcriptional activity (respectively 2,4 and 1,5 fold). The drug lenalidomide induces IKZF1 proteasomal degradation, 52, 53 suggesting that the up-regulation of IKZF1, together with an increase in CCND2 expression could favor disease progression. We also noticed a gain of 5hmC at MAPKAPK2/MK2 at relapse. This gene is located on 1q, which is gained at relapse by this patient, and has been recently described as a poor prognosis factor. 54 At diagnosis, patient MM 5 displayed a classical hyperdiploid profile with amplification of chromosomes 3, 9, 11, 15, 19, where 675 regions were found to harbor 5hmC peak clusters. At relapse 24 months later, cells displayed a 1-copy loss of 17p, with 22 regions (3.2%) significantly decreased. Accordingly to TP53 loss, expression and 5hmC signal of p53 target genes such as MDM2 was found decreased ( Figure 4C ). 55, 56 Patient MM 7 is another MMSET translocated patient (t(4;14)) with amplification of chromosome arm 1q and deletion of chromosomes 13 and 17p ( Figure 4B ) gaining deletions at relapse (3p, 6q, 8q). At relapse, 5hmC increases at several genes such as CDKN2C, IGF2BP3 and WNT5B as well as their RNA expression (log fold-change > 3).
Patient MM 21 plasma cells were found to have a narrow TET2 deletion at diagnosis, but surprisingly 2 heterozygous copies at relapse. TET2, which converts 5mC to 5hmC, is frequently mutated in cancer and especially in myeloid malignancies, 57 but not in MM. 4 385 regions were found to harbour 5hmC, out of which 86 (22%) decreased and 117 (30%) increased at relapse. Global level of 5hmC decreased moderately despite the reappearance of TET2 ( Supplementary Table) .
5hmC and survival in MM
Survival analysis was first performed on the global level of 5mC and 5hmC. 5hmC (indicated as 5hmC/dG [%]) tends to be associated with Overall Survival (OS) although statistically non-significant (Hazard ratio (HR) = 2.6, CI=[0.9,7.8], p value =0.066) ( Figure 5A ). Yet 5hmC is less likely to be associated with Progression-Free Survival (PFS; Figure 5B ; p value =0.3). 5mC global level does not show significant association with OS and PFS ( Supplementary  Figures 8A and 8B) .
Three 5hmC genomic loci were found to separate independently the patients in 2 groups of good and poor survival. High 5hmC signal at the TP53INP1 gene is associated with longer survival (HR=3.7, CI = [1.2-11], p value =0.017; Supplementary Figure 8C ) and low 5hmC signal at RNF144A gene (or UPF1 gene) is associated with poorer survival (data not shown).
The 3 independent 5hmC regions (RNF144A, TP53INP1 and UPF1 ) were then summarized into a score SC1 (see Methods) that separates the cohort into 2 median groups of 20 patients of bad and good outcomes (HR=12, CI= [4, 244] , p value =1 10 -6 for OS; HR=3.8, CI = [1.7, 8.6], p value =4 10 -4 for PFS; Figures 5C and 5D) . The lower risk group shows higher level of 5hmC at TP53INP1 gene and lower levels at RNF144A and UPF1 genes. When applied to gene expression of RNF144A TP53INP1 and UPF1, no significant impact on survival was found (HR=1.4, CI = [0.27, 2.0], p value =0.5; Supplementary Figure 8D ).
We found that 5hmC global level is independent of the 5hmC enrichment at the 3 genomic loci. We combined the 4 variables into a second score SC2 (see Methods). Patients with better outcome show high global level of 5hmC, high 5hmC signal at TP53INP1 and low 5hmC signals at RNF144A and UPF1 (HR=24, CI = [3.2, 187], p value =7 10 -6 for OS; HR=3.8, CI = [1.7, 8.4], p value =6 10 -4 for PFS; Figures 5E and 5F ).
Discussion
We have quantified the epigenetic marks 5mC and 5hmC and mapped 5hmC in plasma cell DNA samples from 40 newly diagnosed MM patients and 5 donors. The global levels of 5mC and 5hmC are lower in MM compared to NPC. 5hmC is higher in Stage I MM compared to Stage II and Stage III patients. 5hmC tends to be positively associated with survival. These observations show that 5hmC is a marker of disease progression and severity.
Despite a global hypohydroxymethylation in MM, there still remain 5hmC marks at transcriptionally active regions. We revealed that 5hmC is strongly associated with active enhancers and identified active genomic regions specific to known MM molecular groups. We also found that H3K27ac-based super-enhancers from Jin and colleagues 39 share similarities with our 5hmC peak clusters. These observations confirm that 5hmC is a valuable mark to study active genomic regions.
An unsupervised analysis shows that 5hmC at major oncogenes (CCND1, CCND2, FGFR3 and MMSET ) can separate hydroxymethylomes of MM patients, consistent with the existing classifications based on genetic abnormalities. 5hmC signals at the loci CCND1 and FGFR3 -MMSET are strong markers of the CCND1 and MMSET molecular groups respectively. This suggests that the translocation events are the major factors shaping MM hydroxymethylome.
We discovered 2 networks of highly correlated 5hmC regions that offer a new prism to view MM transcriptional regulation. Our analysis connects target genes and regulatory regions to transcription factors. The 2 networks are predicted to be controlled by key transcription factors of well-known importance in MM (IRF4, MYC, PRDM1, and XBP1) as well as novel genes associated with the disease regulation (ATF4, IRF7, and TCF3). Of note, several MM-related transcription factors are under investigation to be drug-targeted and represent promising therapeutic targets. 58 The gradual distribution of 5hmC signal between the two networks suggests that they may have redundant functions.
Between diagnosis and relapse, we found a highly dynamic and patient-specific distribution of the 5hmC signal. This reflects that MM progression is highly heterogeneous, although we could find consistency between 5hmC changes, expression and copy number variations.
We found 3 5hmC regions that were independently associated with overall survival. A high 5hmC signal at the TP53INP1 gene is associated with a longer survival while low 5hmC signals at RNF144A and UPF1 genes are associated with good outcome. TP53INP1 protein is shown as a tumor suppressor with antiproliferative and proapoptotic functions. 59, 60 Interestingly, the association of TP53INP1 and overall survival is independent of del17p status.
Our study shows that the epigenetic mark 5hmC is valuable to discover active regulatory regions in genomic DNA from a cohort of patients without the need of chromatin extraction. It has been recently shown that it is also possible to map 5hmC on circulating DNA. 22, 23 This makes 5hmC not only biologically valuable but also technically easier than ChIP-seq against histone marks or transcription factors. Taken together, these results show the value of epigenomics in retrospective studies and bring to light potential drug targets that drive the malignant transcriptome. Supplementary Figure 2 : Criteria of 5hmC peaks to merge in 5hmC peak clusters. The y-axis represents the number of peaks left after merging. The x-axis represents the distance between peaks to merge. Each 5hmC samples were analyzed (one color per patient). The distance 12.5 kb was chosen to define the 5hmC peak clusters that we used in this study.
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